You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 162 No. 6, March 25, 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Review Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (17)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Cardiovascular System
 •Randomized Controlled Trial
 •Congestive Heart Failure/ Cardiomyopathy
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Benefits of {beta}-Blocker Therapy for Heart Failure

Weighing the Evidence

Sidney Goldstein, MD

Arch Intern Med. 2002;162:641-648.

Our understanding of factors contributing to the progression of heart failure has advanced dramatically over the past 2 decades. We have also gained considerable insight into the pharmacology of {beta}-adrenergic receptor blockers ({beta}-blockers). Based on this knowledge, we can now appreciate the potential of these drugs for the treatment of heart failure. Several {beta}-blockers have been shown to be clinically effective in the treatment of heart failure. Critical evaluation of the evidence from basic research studies, as well as clinical trials in patients with heart failure, helps to delineate the theoretical and clinical benefits of {beta}-blockers.


From the Division of Cardiovascular Medicine, Henry Ford Heart and Vascular Institute, Detroit, Mich.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cardiac 12/15 lipoxygenase-induced inflammation is involved in heart failure
Kayama et al.
JEM 2009;206:1565-1574.
ABSTRACT | FULL TEXT  

G Protein-Coupled Receptor Kinase 2 Ablation in Cardiac Myocytes Before or After Myocardial Infarction Prevents Heart Failure
Raake et al.
Circ. Res. 2008;103:413-422.
ABSTRACT | FULL TEXT  

Anti-{beta}1AR antibodies in dilated cardiomyopathy: Are these a new class of receptor agonists?
Hebert
Cardiovasc Res 2007;76:5-7.
FULL TEXT  

Navigating the Crossroads of Coronary Artery Disease and Heart Failure
Gheorghiade et al.
Circulation 2006;114:1202-1213.
FULL TEXT  

Preserved left ventricular structure and function in mice with cardiac sympathetic hyperinnervation
Kiriazis et al.
Am. J. Physiol. Heart Circ. Physiol. 2005;289:H1359-H1365.
ABSTRACT | FULL TEXT  

Simple Clinical Criteria to Determine the Prognosis of Heart Failure
Heywood et al.
J CARDIOVASC PHARMACOL THER 2005;10:173-180.
ABSTRACT  

Influence of supplemental magnesium, tryptophan, vitamin C, and vitamin E on stress responses of pigs to vibration
Peeters et al.
J ANIM SCI 2005;83:1568-1580.
ABSTRACT | FULL TEXT  

Pursuing integration of performance measures into electronic medical records: beta-adrenergic receptor antagonist medications
Weiner et al.
Qual Saf Health Care 2005;14:99-106.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.